18F-Florbetaben: A New Tool for Amyloidosis Staging?

Emmanuel d'Estanque (1) , Benjamin Chambert , Olivier Moranne (1, 2) , Pierre Olivier Kotzki (1, 3) , Vincent Boudousq (1, 3)

1 CHU Nîmes - Centre Hospitalier Universitaire de Nîmes
2 AIDMP - Aide à la Décision pour une Médecine Personnalisé - Laboratoire de Biostatistique, Epidémiologie et Recherche Clinique - EA 2415
3 IRCM - U1194 Inserm - UM - Institut de Recherche en Cancérologie de Montpellier

We report the case of a 73-year-old man with a documented (renal biopsy) light-chain amyloidosis (AL) imaged with F-AV-1 (F-florbetaben) compared with a volunteer. A cardiac amyloidosis was suspected. As it was an AL and not a transthyretin amyloidosis, F-FDG and F-florbetaben PET/CT were preferred to bone scan. F-FDG scintigraphy showed a focal cardiac hypermetabolism. In addition of the heart, F-florbetaben scintigraphy showed an intense spleen and thyroid pathologic uptake and a moderate salivary gland and kidney uptake. F-florbetaben PET/CT appears to be useful for staging systemic amyloidosis.

Domaines: Imagerie; Médecine nucléaire; Médecine humaine et pathologie

Emmanuel d'Estanque, Benjamin Chambert, Olivier Moranne, Pierre Olivier Kotzki, Vincent Boudousq. 18F-Florbetaben: A New Tool for Amyloidosis Staging?. Clinical Nuclear Medicine, 2017, 42 (1), pp.50 - 53. ⟨10.1097/RLU.0000000000001434⟩. ⟨hal-01900477⟩